NASDAQ: CGON

CG Oncology (CGON) Stock Analysis & Forecast

Nov 13 close

$74.40+4.25 (+6.1%)

Gekko Brief

AI summaryNov 9 close

CG Oncology moved sharply this week after its third-quarter results, which showed revenue of $1.6 million, beating a consensus of $1.08 million, alongside a narrower-than-expected per-share loss relative to some estimates, even as reported EPS of ($0.64) missed by $0.04 against another estimate. The quarter's net loss widened to $56.9 million from $43.8 million a year earlier, with a nine-month net loss of $196.1 million, though the company holds $984.5 million in cash, cash equivalents and marketable securities. Coverage also pointed to positive updates on the company's late-stage bladder cancer programs, including cretostimogene grenadenorepvec, which helped support the stock's reaction.

CGON closed at $74.74, down 1.6% on the day, but remains above both its 50-day average of $68.24 and its 200-day average of $66.30, with the 50-day above the 200-day. The GekkoIndex reads 44.1, placing the stock in the Distribution zone, down 20 points over five sessions. Shares trade 3.4% below Gekko Fair Value of $77.38, within the 52-week range of $35.80 to $80.97.

The next earnings date falls on 26 February 2027, 108 days out, outside a typical 20-trading-day hold. No insider, Congress or unusual options activity appears in the current windows. Analyst coverage from 7 firms is unanimously rated buy, with a consensus target of $91.08, implying 21.9% upside. A filing shows Candriam S.C.A. trimmed its position by 20% during the period.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

CG Oncology price vs fair value

$77.41$74.40Nov ’25May ’26Nov ’26
Close $74.40200-day averageGekko Fair Value $77.41

CG Oncology quick facts

Market cap
$6.65B
P/E ratio
—
Forward P/E
—
EPS, TTM
−$2.76
Revenue, TTM
$6.17M
Profit margin
0%
Dividend yield
—
Beta
0.35
Volume
3.24M avg 1.20M
1-year return
+88.8%
Typical daily move
±6.7%
Typical 20-day move
±8.8%
50-day average
$68.04
200-day average
$66.68
Next earnings
Feb 26
Shares outstanding
89.32M
52-week range
$37.01$80.97

CG Oncology swing-trade checklist

CG Oncology scores 2 supportive, 2 mixed and 0 headwinds across the 4 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

2 supportive2 mixed0 headwinds

  • Trendsupportive

    Above 50 and 200-day

    Close $74.40 is above the 50-day ($68.04) and 200-day ($66.68) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    47.3, Neutral

    Reading 47.3 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuemixed

    3.9% below

    Price is within 5% of Gekko Fair Value (3.9% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 103 days

    Next report Feb 26, 2027, 103 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityno data

    No data

    Not enough years of history for a seasonal read.

A description of current data, not a recommendation. How this page works

CG Oncology stock chart and price history

CG Oncology closed at $74.40 on Nov 13, 2026, +88.8% over the past year, inside a 52-week range of $37.01 to $80.97.

Close50-day average200-day averageVolume
CG Oncology share price, past year, with 50-day and 200-day moving averages and volume$30$40$50$60$70$80DecJan 2026FebMarAprMayJunJulAugSepOctNov74.40

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+20.3%
3 months
−3.5%
6 months
+11.2%
1 year
+88.8%
The full CGON chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open CGON in Gekko

Follow CG Oncology through every session

Put CGON on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track CGON in GekkoFree for 7 days. No credit card required.

About CG Oncology

CG Oncology is a late-stage clinical biopharmaceutical company focused on treating bladder cancer in the United States. Its work centers on a single investigational therapy, cretostimogene grenadenorepvec, an oncolytic immunotherapy being studied across multiple stages of bladder cancer, including cases where prior BCG treatment has failed and cases considered high risk or intermediate risk.

The company runs a series of clinical programs testing cretostimogene both as a standalone treatment and in different patient groups, including those with BCG-unresponsive disease, papillary tumors, and patients following surgical removal of tumors through TURBT. These programs span phase 2 and phase 3 trials, each designed to examine safety and effectiveness of the therapy in a specific bladder cancer population. As a clinical-stage company, its business is built around advancing this pipeline of trials rather than selling an approved product.

CG Oncology was founded in 2010 under the name Cold Genesys, Inc. and adopted its current name in June 2020. It is headquartered in Irvine, California, and its shares are listed on the NASDAQ under the ticker CGON.

Listed
NASDAQ
Sector
Health technology
Industry
Biotechnology
Website
cgoncology.com

CG Oncology GekkoIndex: the smart money zone

CG Oncology’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 47.3, in the Neutral zone, up 1 point over five sessions.

010047.3Neutral

Up 1 point over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying38+4.0%+10.1%+16.7%+14.0%
Accumulation197+1.9%+4.1%+4.3%+9.2%
Neutral (current zone)423+0.1%−0.4%+0.3%+4.5%
Distribution35−0.2%+1.5%+4.1%+9.5%
Selling2Too few readings yet

Average CGON share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the CGON price, zone by zone.Track CGON in Gekko

Is CG Oncology stock overvalued? Gekko Fair Value

CG Oncology trades 3.9% below Gekko Fair Value of $77.41, so the shares are about fair value on Gekko’s estimate.

Gekko’s own estimate of what CG Oncology shares are worth, recalculated every trading day.

$77.41

Gekko Fair Value, Nov 14, 2026

3.9% below fair value · About fair value

At the end of Aug 2026 the price was 12.2% below the estimate.

Gekko Fair ValueShare price, month end
$77$74Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open CGON in Gekko

CG Oncology insider and Congress trading

No open-market insider purchases were filed for CG Oncology, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for CGON in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every CGON insider filing, plotted on the chart in Gekko.Open CGON in Gekko

Congress trades last 90 days

No trades in CGON were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for CGON, plotted on the chart in Gekko.Open CGON in Gekko

Hedge funds and billionaires quarter ended Jun 30

2of the funds Gekko tracks hold CGON.

1added1opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko

CG Oncology earnings: next date and track record

CG Oncology reports on Feb 26, 2027 (103 days away), and beat the EPS estimate in 2 of its last 8 reports.

2 of 8reports beat the EPS estimate
±4.6%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

−6.4%Nov ’24−9.1%Mar ’25−3.9%May ’25−1.6%Aug ’25+9.2%Nov ’25+2.9%Feb ’26+0.2%May ’26+3.7%Aug ’26
ReportedEPSSurpriseRevenueSurpriseMove
Aug 6, 2026−$0.90
est −$0.66
−35.5%$1.16M
est $361K
+220.7%+3.7%
May 8, 2026−$0.71
est −$0.58
−22.4%$1.08M
est $453K
+139.1%+0.2%
Feb 27, 2026−$0.51
est −$0.61
+16.4%$2.30M
est $451K
+410.5%+2.9%
Nov 14, 2025−$0.57
est −$0.56
−2.0%$1.67M
est $59K
+2,706.4%+9.2%
Aug 8, 2025−$0.54
est −$0.49
−10.2%—
est $82K
—−1.6%
May 13, 2025−$0.45
est −$0.39
−15.4%$52K
est $118K
−56.0%−3.9%
Mar 28, 2025−$0.48
est −$0.41
−17.1%$456K
est $124K
+267.9%−9.1%
Nov 14, 2024−$0.30
est −$0.42
+28.6%——−6.4%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

CG Oncology stock forecast and analyst price targets

Analysts’ average 12-month price target for CG Oncology is $91.46, +22.9% from the last close, from 7 firms rating the stock in the last 90 days.

$91.46consensus 12-month target, +22.9% from the last close
Low $84High $102
Buy7
Hold0
Sell0

Each firm’s latest rating in the last 90 days: 7 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 13Morgan StanleyBuy, reiterated$102+37.1%
Nov 9WedbushBuy, reiterated$84+12.9%
Nov 9GuggenheimBuy, maintained$89+19.6%
Nov 6JonesTradingBuy, maintained$85+14.2%
Nov 6H.C. WainwrightBuy, maintained$100+34.4%
+0.3%average 20-day move after past Neutral readings
±6.7%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

CG Oncology market cap and key statistics

CG Oncology’s market cap is $6.65B and revenue of $6.17M over the last twelve months.

Valuation

Market cap
$6.65B
EPS, TTM
−$2.76
Gekko Fair Value
$77.41

Trading

Volume
3.24M
Avg volume, 20 days
1.20M
52-week high
$80.97
52-week low
$37.01
Shares outstanding
89.32M

Financials

Revenue, TTM
$6.17M
Profit margin
0%
Return on equity
-28.3%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
0.35
Typical daily move
±6.7%
Typical 20-day move
±8.8%

CG Oncology stock news this week

Coverage of CG Oncology this week reads positive: 4 positive, 1 neutral and 2 negative headlines.

News sentiment positive

CG Oncology peers

CG Oncology’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
AMGNAmgen−0.4%Neutral19.9% below
GILDGilead Sciences−0.3%Neutral11.7% above
MRNAModerna−0.7%Neutral21.1% above
NTRANatera−1.8%Accumulation18.6% below
IQVIQVIA−2.4%Accumulation5.0% above
UTHRUnited Therapeutics−0.4%Neutral11.2% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Biotechnology

CG Oncology stock FAQ

What is CG Oncology’s market cap?

CG Oncology’s market cap is $6.65B at the Nov 13, 2026 close of $74.40, with 89.32M shares outstanding.

What is the CG Oncology stock forecast?

The consensus analyst 12-month price target for CG Oncology is $91.46, +22.9% from the last close. Of the 7 firms that rated the stock in the last 90 days, 7 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is CG Oncology stock overvalued or undervalued?

On Gekko’s estimate CG Oncology is about fair value: the Nov 13, 2026 close of $74.40 is 3.9% below Gekko Fair Value of $77.41. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does CG Oncology report earnings next?

CG Oncology is expected to report on Feb 26, 2027 (103 days away). Analysts expect earnings of −$0.71 per share on revenue of $886K. CG Oncology beat the earnings estimate in 2 of its last 8 reports, moving 4.6% on average across the report.

What is CG Oncology’s 52-week high and low?

CG Oncology’s 52-week high is $80.97 and its 52-week low is $37.01; it closed at $74.40 on Nov 13, 2026, +88.8% over the past year.

Is CG Oncology stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 4 items with data read as supportive (trend and earnings risk), 2 as mixed (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See CG Oncology the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.